share_log

AbbVie | 144: Notice of proposed sale of securities pursuant to Rule 144

艾伯维公司 | 144:拟议出售证券

美股sec公告 ·  02/29 16:17
Moomoo AI 已提取核心信息
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
根据最近的一份文件,艾伯维公司高管佩里·西亚蒂亚斯定于2024年2月29日出售该公司的9,911股普通股。这些股票的总市值为1,756,912.07美元,于2024年2月28日作为绩效股票直接从发行人手中收购。该交易遵循了西亚蒂亚斯在过去三个月中的近期销售记录,共计16,672股股票,总收益为2,937,556.66美元。计划中的出售是2023年11月1日通过的交易计划的一部分。
根据最近的一份文件,艾伯维公司高管佩里·西亚蒂亚斯定于2024年2月29日出售该公司的9,911股普通股。这些股票的总市值为1,756,912.07美元,于2024年2月28日作为绩效股票直接从发行人手中收购。该交易遵循了西亚蒂亚斯在过去三个月中的近期销售记录,共计16,672股股票,总收益为2,937,556.66美元。计划中的出售是2023年11月1日通过的交易计划的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息